BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ARTES Biotechnology Steps Further into the Vaccine Business by Acquiring Anavax


9/27/2010 12:35:40 PM

Langenfeld, September 27, 2010 -- ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases.

With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique partner for the vaccine industry.

The ANAVAX VLP platform has already been applied to the development of adjuvant-free vaccines against avian and swine flu, malaria and HIV. Hansenula is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns. Together, the platforms build a new approach to low-cost mass production of safe and effective vaccines. ARTES’ business plan is to enhance its position as a preferred development partner for vaccine manufacturer.

Virus-like particles: VLPs VLPs are small packages of artificially produced viral proteins that assemble either spontaneously or are embedded in a lipid membrane during protein synthesis. As a safe and efficient technology platform, VLPs are of increasing interest for the presentation of new antigens. The structural similarity to viruses together with the complete lack of infectious material is a major advantage over conventional vaccines.

Anavax

The ANAVAX technology was developed by scientists at the Burnet Institute in Melbourne. First vaccine candidates targeting different flu viruses, malaria, HIV and HCV showed positive results in preclinical studies. The Burnet Institute and ARTES will further collaborate to develop processes for specific vaccines.

ARTES’ Hansenula platform

This yeast expression platform has been applied to the production of more immunogenic hepatitis B VLP vaccines and provides an excellent base for balanced co-expression of individual proteins. The reliability and attractiveness of the Hansenula platform has been demonstrated by a number of products already marketed worldwide and by several others in clinical trials.

ARTES Biotechnology GmbH – www.artes-biotechnology.com

ARTES is a Germany-based biotechnology company specialized in recombinant protein production and process development in microbial expression systems. ARTES offers generation of optimized production cell lines and process development based on proprietary technologies. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850-square meter S1 facilities in Langenfeld near Duesseldorf. The company focuses on contract R&D for white and red biotechnology products and on the development of new vaccine targets.

ARTES Biotechnology GmbH Dr. Melanie Piontek Business Development Director +49 (0)2173 275870 piontek@artes-biotechnology.com

Elisabeth-Selbert-Straße 9 40764 Langenfeld



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES